Long-acting VIP formulations for the treatment of chronic inflammatory diseases

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43AI082723-01
Agency Tracking Number: AI082723
Amount: $600,000.00
Phase: Phase I
Program: SBIR
Awards Year: 2009
Solicitation Year: 2009
Solicitation Topic Code: N/A
Solicitation Number: PHS2009-2
Small Business Information
720 BROADWAY, STE 511, SEATTLE, WA, 98122
DUNS: 167580682
HUBZone Owned: Y
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 (206) 568-1494
Business Contact
Phone: (206) 860-6769
Email: ebolotin@pharmain.com
Research Institution
DESCRIPTION (provided by applicant): Despite the success of TNF-inhibitors and other new biological drugs for the treatment of autoimmune and other chronic inflammatory diseases, there are still many patients that are only poorly controlled. Vasoactive intestinal peptide (VIP) is an immunomodulatory peptide that induces regulatory T-cells and anti-inflammatory cytokine responses and has shown efficacy in numerous rodent models of autoimmune diseases with predominant TH1-type immune responses. Use of VIP in humans is severely hindered by its short in vivo half-life, and the therapeutic window is limited by the vasodilatory properties of this peptide that can cause an unsafe drop in blood pressure upon injection. Formulating VIP into a nanocarrier can improve both properties as the binding to the nanocarrier sequesters it from degrading enzymes and excretion by the kidney. The binding of VIP to a nanocarrier also decreases the concentration of free VIP in serum, thereby decreasing the blood pressure drop and increasing the therapeutic window. In this application two different nanocarriers will be compared in their ability to formulate VIP for the treatment of chronic inflammatory diseases. The nanocarriers are a Protected Graft Copolymer (PGC), in which a poly-lysine backbone is grafted with polyethylene glycol (PEG) side chains. The load-molecule will bind to specific residues between the PEG-side chains. The other nanocarrier consists of a sterically stabilized micelle (SSM). These different nanocarrier-VIP formulations will be compared in terms of efficacy in collagen induced arthritis, a mouse model of rheumatoid arthritis. Additionally, the pharmacokinetics of the different nanocarrier-VIP formulations will be determined. Toxicity will be tested using non-invasive blood pressure monitors that measure peripheral arterial pressure in the tail with an inflatable tail cuff, in addition to monitoring general parameters of health (behavior, appearance, diarrhea etc). PUBLIC HEALTH RELEVANCE: Vasoactive intestinal peptide (VIP) is a hormone in the human body that can be used for the treatment of autoimmune diseases in animal models. Rapid degradation and side effects at high dose have so far limited VIP use in humans. In this project VIP will be formulated into forms that will deal with these problems that will allow its universal use in many human diseases.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government